Echinomycin (NSC 526417) in recurrent and metastatic squamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group (GOG).
Nineteen evaluable patients with recurrent or metastatic squamous cell carcinoma of the uterine cervix were treated with 1,500 micrograms/m2 of echinomycin every 4 weeks. No patient had received prior chemotherapy. There was one partial response (5% response, 95% confidence interval for response of 0% to 26%). The major toxicity was nausea and vomiting which was moderate to severe in six patients. Myelosuppression was not observed. Echinomycin, in this dose and schedule displays no major activity in chemotherapy-naive patients with advanced squamous-cell carcinoma of the cervix.
Muss
H B
HB
Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC.
Blessing
J A
JA
Eddy
G L
GL
McGehee
R
R
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D004341:Drug Evaluation; D004448:Echinomycin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
D004448:Echinomycin